By accelerating your access to the right patients and expertise, we accelerate your access to efficacy data.
Your journey advances more smoothly when you can show regulators and financial stakeholders early on that your new molecule is effective. That’s why PAREXEL® has developed an integrated and adaptive approach that supports Phase IIa outcomes. From early phase trials that can take you into Proof-of-Concept studies through to product launch, we can activate the appropriate patient populations, biostatistical expertise, and ePro technologies you need, when and where you need them. PAREXEL provides the right resources in the right places, customized to provide the data you need to expedite your objectives.